Xu L - Search Results

1

A fluorescence-based thermal shift assay identifies inhibitors of mitogen activated protein kinase kinase 4.

Krishna SN, Luan CH, Mishra RK, Xu L, Scheidt KA, Anderson WF, Bergan RC. Krishna SN, et al. Among authors: xu l. PLoS One. 2013 Dec 5;8(12):e81504. doi: 10.1371/journal.pone.0081504. eCollection 2013. PLoS One. 2013. PMID: 24339940 Free PMC article.

2

Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis.

Pavese JM, Ogden IM, Voll EA, Huang X, Xu L, Jovanovic B, Bergan RC. Pavese JM, et al. Among authors: xu l. PLoS One. 2014 Jul 14;9(7):e102289. doi: 10.1371/journal.pone.0102289. eCollection 2014. PLoS One. 2014. PMID: 25019290 Free PMC article.

3

Precision therapeutic targeting of human cancer cell motility.

Xu L, Gordon R, Farmer R, Pattanayak A, Binkowski A, Huang X, Avram M, Krishna S, Voll E, Pavese J, Chavez J, Bruce J, Mazar A, Nibbs A, Anderson W, Li L, Jovanovic B, Pruell S, Valsecchi M, Francia G, Betori R, Scheidt K, Bergan R. Xu L, et al. Nat Commun. 2018 Jun 22;9(1):2454. doi: 10.1038/s41467-018-04465-5. Nat Commun. 2018. PMID: 29934502 Free PMC article.

4

Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells.

Huang X, Chen S, Xu L, Liu Y, Deb DK, Platanias LC, Bergan RC. Huang X, et al. Among authors: xu l. Cancer Res. 2005 Apr 15;65(8):3470-8. doi: 10.1158/0008-5472.CAN-04-2807. Cancer Res. 2005. PMID: 15833883

5

Genistein inhibits matrix metalloproteinase type 2 activation and prostate cancer cell invasion by blocking the transforming growth factor beta-mediated activation of mitogen-activated protein kinase-activated protein kinase 2-27-kDa heat shock protein pathway.

Xu L, Bergan RC. Xu L, et al. Mol Pharmacol. 2006 Sep;70(3):869-77. doi: 10.1124/mol.106.023861. Epub 2006 Jun 13. Mol Pharmacol. 2006. PMID: 16772519

6

MEK4 function, genistein treatment, and invasion of human prostate cancer cells.

Xu L, Ding Y, Catalona WJ, Yang XJ, Anderson WF, Jovanovic B, Wellman K, Killmer J, Huang X, Scheidt KA, Montgomery RB, Bergan RC. Xu L, et al. J Natl Cancer Inst. 2009 Aug 19;101(16):1141-55. doi: 10.1093/jnci/djp227. Epub 2009 Jul 28. J Natl Cancer Inst. 2009. PMID: 19638505 Free PMC article. Clinical Trial.

7

Heat shock protein 27 regulates human prostate cancer cell motility and metastatic progression.

Voll EA, Ogden IM, Pavese JM, Huang X, Xu L, Jovanovic BD, Bergan RC. Voll EA, et al. Among authors: xu l. Oncotarget. 2014 May 15;5(9):2648-63. doi: 10.18632/oncotarget.1917. Oncotarget. 2014. PMID: 24798191 Free PMC article.

8

Dietary genistein inhibits metastasis of human prostate cancer in mice.

Lakshman M, Xu L, Ananthanarayanan V, Cooper J, Takimoto CH, Helenowski I, Pelling JC, Bergan RC. Lakshman M, et al. Among authors: xu l. Cancer Res. 2008 Mar 15;68(6):2024-32. doi: 10.1158/0008-5472.CAN-07-1246. Cancer Res. 2008. PMID: 18339885

9

Genistein treatment duration effects biomarkers of cell motility in human prostate.

Zhang H, Gordon R, Li W, Yang X, Pattanayak A, Fowler G, Zhang L, Catalona WJ, Ding Y, Xu L, Huang X, Jovanovic B, Kelly DL, Jiang H, Bergan R. Zhang H, et al. Among authors: xu l. PLoS One. 2019 Mar 27;14(3):e0214078. doi: 10.1371/journal.pone.0214078. eCollection 2019. PLoS One. 2019. PMID: 30917169 Free PMC article. Clinical Trial.

10

Genistein induces phenotypic reversion of endoglin deficiency in human prostate cancer cells.

Craft CS, Xu L, Romero D, Vary CP, Bergan RC. Craft CS, et al. Among authors: xu l. Mol Pharmacol. 2008 Jan;73(1):235-42. doi: 10.1124/mol.107.038935. Epub 2007 Oct 19. Mol Pharmacol. 2008. PMID: 17951357

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

42,170 results

Search Page

Filters